In this sense, studies using patient-derived xenografts (PDXs) and LUAD tumors from Keap1-deficient mice have shown an increased sensitivity to glutaminase inhibition (the enzyme that generates glutamate from glutamine), sensitizing KEAP1/NRF2 mutant NSCLC cells to radiotherapy [110,111]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.